The North America Alzheimer’s disease therapeutics & diagnostics market is anticipated to surge with a 6.46% CAGR during the forecast years between 2022 and 2030, generating $4335.77 million in revenue by 2030.
NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030
North America Alzheimer’s Disease Market by Therapeutics & Diagnostics (Therapeutics (Drugs, Disease Stage, Generic & Branded) Diagnostics (Lumbar Puncture Test, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Blood Test, Other Diagnostics)) by Geography
The North America Alzheimer’s disease therapeutics & diagnostics market is anticipated to surge with a 6.46% CAGR during the forecast years between 2022 and 2030, generating $4335.77 million in revenue by 2030.
Due to the prospect of new therapies gaining market approval and the anticipated growth in sales of the extended-release formulation of Namenda, Namenda XR, the market for Alzheimer’s Disease Therapeutics and Diagnostics is anticipated to grow in North America. The government institutions are also focusing on the innovations and development of Alzheimer’s therapeutics and diagnostics, further augmenting the growth of the North America market during the forecast years.
To know more about this report, request a free sample copy
The North America Alzheimer’s disease therapeutics & diagnostics market growth assessment entails the evaluation of United States and Canada. The United States is the largest player in Alzheimer’s disease diagnostics and therapeutics market. According to the National Institutes of Health (NIH), in 2020, around 5.8 million Americans lived with Alzheimer’s. Out of them, 81% were aged 75 or above. Further, medications and long-term care costs for individuals with Alzheimer’s or other dementias are substantial. However, apart from high prevalence rates and expenditure on disease management, the country also has high detection rates in primary care settings.
On the other hand, according to the Alzheimer Society of Canada, about 25,000 new cases of dementia are being diagnosed every year. By 2031, the number is expected to rise to 937,000, an increase of 66%, as nearly 25,000 new cases of dementia are diagnosed every year. Alzheimer’s disease is the most common cause of dementia, contributing to around 64% of all cases of dementia. Growing at its current rate, AD will cost caregivers and the healthcare system a cost of $16.6 billion a year by 2031.
The North America Alzheimer’s disease therapeutics & diagnostics market segmentation analysis includes therapeutics & diagnostics.
Generic & branded therapeutics are an important segment of the market. Branded medicine is the original product that a pharmaceutical company has developed. When new medicines are manufactured, they must undergo rigorous evaluations and tests to ensure safety for usage and curing effectiveness. As pharmaceutical companies invest considerably to develop new medicines, they are provided with sole rights to distribute and manufacture them.
On the other hand, generic drugs are copies of brand-name drugs with the same effects, dosage, side effects, intended use, risks, safety, strength, and route of administration as the original drug. Their pharmacology is the same as their brand-name counterparts.
Some key players in the North America Alzheimer’s disease therapeutics & diagnostics market are Baxter International Inc, Eli Lilly & Company, GE Healthcare, and Johnson & Johnson.
Eli Lilly & Company is a pharmaceutical company that manufactures, discovers, develops, and sells pharmaceutical and animal health products. The company offers human pharmaceutical products in the therapeutic areas of endocrinology, neuroscience, cardiovascular, immunology, and oncology. It also develops, manufactures, and markets products for food animals and companion animals. The company distributes its products through online healthcare channels, sales representatives, and wholesalers. Eli Lilly offers its products to hospitals, physicians, pharmacies, and other healthcare professionals. It has a business presence in the US, Japan, Europe, and other countries. The company is headquartered in Indianapolis, United States.
Solanezumab is a monoclonal anti-amyloid antibody from Eli Lilly & Company, which is in the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) study in preclinical Alzheimer’s disease cure. The A4 clinical trial tests the effects of solanezumab in older individuals without showing symptoms of memory impairment but with evidence of amyloid synthesis in their brains.
Report Synopsis
| Report Scope | Details |
| Market Forecast Years | 2022-2030 |
| Base Year | 2021 |
| Market Historical Years | 2018-2021 |
| Forecast Units | Revenue ($ Million) |
| Segments Analyzed | Therapeutics & Diagnostics |
| Countries Analyzed | United States and Canada |
| Companies Analyzed |
Allergan PLC, Amarantus, BioScience Holdings Inc, Baxter International Inc, Biogen Inc, Cognoptix Inc, Eisai Co Ltd, Eli Lilly & Company, F Hoffmann-La Roche, GE Healthcare, Johnson & Johnson, Lupin Limited, Merck & Co Inc, Novartis AG, Pfizer Inc, Siemens Healthineers AG, Sun Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Limited, Zydus Cadila |
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- PARENT MARKET ANALYSIS
- KEY DRIVERS
- GROWING GERIATRIC POPULATION
- RISING PERVASIVENESS OF ALZHEIMER’S DISEASE
- EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
- INCREASING PIPELINE DRUGS
- KEY RESTRAINTS
- FAILURE OF THE LATE-STAGE DRUGS
- STRINGENT GOVERNMENT REGULATIONS
- LACK OF THE AVAILABILITY OF SURROGATE MARKERS
- KEY ANALYTICS
- TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
- PHASES AND STERNNESS OF ALZHEIMER’S DISEASE
- IMPACT OF COVID-19 ON ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
- BUYERS POWER
- SUPPLIERS POWER
- SUBSTITUTION
- NEW ENTRANTS
- INDUSTRY RIVALRY
- KEY BUYING CRITERIA
- SUPPLY CHAIN ANALYSIS
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- MARKET BY THERAPEUTICS & DIAGNOSTICS
- THERAPEUTICS
- DRUGS
- MARKETED DRUGS
- PIPELINE DRUGS
- DISEASE STAGE
- LATE-STAGE: SEVERE AD
- EARLY/MIDDLE STAGE: MILD TO MODERATE AD
- PRODROMAL STAGE
- GENERIC & BRANDED
- BRANDED
- GENERIC
- DRUGS
- DIAGNOSTICS
- LUMBAR PUNCTURE TEST
- POSITRON EMISSION TOMOGRAPHY
- ELECTROENCEPHALOGRAPHY
- MAGNETIC RESONANCE IMAGING
- COMPUTED TOMOGRAPHY
- BLOOD TEST
- OTHER DIAGNOSTICS
- THERAPEUTICS
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- UNITED STATES
- CANADA
- NORTH AMERICA
- COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
- MERGERS & ACQUISITIONS
- PRODUCT LAUNCHES & DEVELOPMENTS
- PARTNERSHIPS & AGREEMENTS
- BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
- COMPANY PROFILES
- ALLERGAN PLC (ACQUIRED BY ABBVIE)
- AMARANTUS BIOSCIENCE HOLDINGS INC
- BAXTER INTERNATIONAL INC
- BIOGEN INC
- COGNOPTIX INC
- EISAI CO LTD
- ELI LILLY & COMPANY
- F HOFFMANN-LA ROCHE
- GE HEALTHCARE
- JOHNSON & JOHNSON
- LUPIN LIMITED
- MERCK & CO INC
- NOVARTIS AG
- PFIZER INC
- SIEMENS HEALTHINEERS AG
- SUN PHARMACEUTICALS INDUSTRIES LTD
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- ZYDUS CADILA
- KEY STRATEGIC DEVELOPMENTS
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS
TABLE 2: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 3: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 4: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 5: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 6: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 7: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 8: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 9: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 10: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 11: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 12: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 13: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
TABLE 14: LEADING PLAYERS OPERATING IN NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 15: LIST OF MERGERS & ACQUISITIONS
TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 17: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 18: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
LIST OF FIGURES
FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE
FIGURE 2: KEY MARKET TRENDS
FIGURE 3: PORTER’S FIVE FORCES ANALYSIS
FIGURE 4: KEY BUYING CRITERIA
FIGURE 5: SUPPLY CHAIN ANALYSIS
FIGURE 6: OPPORTUNITY MATRIX
FIGURE 7: VENDOR LANDSCAPE
FIGURE 8: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021
FIGURE 9: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2030 (IN $ MILLION)
FIGURE 10: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021
FIGURE 11: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2030 (IN $ MILLION)
FIGURE 12: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2030 (IN $ MILLION)
FIGURE 13: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021
FIGURE 14: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2030 (IN $ MILLION)
FIGURE 15: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2030 (IN $ MILLION)
FIGURE 16: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2030 (IN $ MILLION)
FIGURE 17: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021
FIGURE 18: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2030 (IN $ MILLION)
FIGURE 19: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2030 (IN $ MILLION)
FIGURE 20: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2030 (IN $ MILLION)
FIGURE 21: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021
FIGURE 22: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2030 (IN $ MILLION)
FIGURE 23: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2030 (IN $ MILLION)
FIGURE 24: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2030 (IN $ MILLION)
FIGURE 25: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2030 (IN $ MILLION)
FIGURE 26: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2030 (IN $ MILLION)
FIGURE 27: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2030 (IN $ MILLION)
FIGURE 28: NORTH AMERICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2030 (IN $ MILLION)
FIGURE 29: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
FIGURE 30: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
FIGURE 31: CANADA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- UNITED STATES
- CANADA
- NORTH AMERICA
- MARKET BY THERAPEUTICS & DIAGNOSTICS
- THERAPEUTICS
- DRUGS
- MARKETED DRUGS
- PIPELINE DRUGS
- DISEASE STAGE
- LATE-STAGE: SEVERE AD
- EARLY/MIDDLE STAGE: MILD TO MODERATE AD
- PRODROMAL STAGE
- GENERIC & BRANDED
- BRANDED
- GENERIC
- DRUGS
- DIAGNOSTICS
- LUMBAR PUNCTURE TEST
- POSITRON EMISSION TOMOGRAPHY
- ELECTROENCEPHALOGRAPHY
- MAGNETIC RESONANCE IMAGING
- COMPUTED TOMOGRAPHY
- BLOOD TEST
- OTHER DIAGNOSTICS
- THERAPEUTICS
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.